Sangamo Therapeutics (NASDAQ:SGMO) Earns “Buy” Rating from HC Wainwright

Sangamo Therapeutics (NASDAQ:SGMO)‘s stock had its “buy” rating restated by investment analysts at HC Wainwright in a research report issued to clients and investors on Monday,Benzinga reports. They presently have a $10.00 target price on the biopharmaceutical company’s stock.

Other analysts have also recently issued research reports about the stock. Barclays boosted their price objective on shares of Sangamo Therapeutics from $3.00 to $9.00 and gave the stock an “overweight” rating in a research note on Thursday, November 14th. Wells Fargo & Company dropped their target price on shares of Sangamo Therapeutics from $3.00 to $2.00 and set an “equal weight” rating on the stock in a research report on Tuesday, December 31st. StockNews.com lowered Sangamo Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, December 24th. Truist Financial dropped their price objective on shares of Sangamo Therapeutics from $7.00 to $5.00 and set a “buy” rating on the stock in a research note on Thursday. Finally, Jefferies Financial Group cut their target price on Sangamo Therapeutics from $7.00 to $3.00 and set a “buy” rating on the stock in a research report on Tuesday, December 31st. Three research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $5.17.

Sangamo Therapeutics Price Performance

Shares of SGMO opened at $1.16 on Monday. The firm has a 50 day simple moving average of $1.81 and a two-hundred day simple moving average of $1.32. The company has a market cap of $242.03 million, a P/E ratio of -1.55 and a beta of 1.29. Sangamo Therapeutics has a one year low of $0.30 and a one year high of $3.18.

Sangamo Therapeutics (NASDAQ:SGMO) last issued its earnings results on Tuesday, November 12th. The biopharmaceutical company reported $0.04 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.07. The firm had revenue of $49.41 million for the quarter, compared to analyst estimates of $26.55 million. Sangamo Therapeutics had a negative net margin of 257.87% and a negative return on equity of 264.16%. During the same quarter last year, the business posted ($0.34) earnings per share. On average, analysts expect that Sangamo Therapeutics will post -0.47 earnings per share for the current fiscal year.

Institutional Trading of Sangamo Therapeutics

A number of institutional investors have recently modified their holdings of SGMO. Shelton Wealth Management LLC bought a new position in shares of Sangamo Therapeutics in the fourth quarter worth $29,000. Cubist Systematic Strategies LLC purchased a new stake in Sangamo Therapeutics during the 2nd quarter worth about $67,000. Meritage Portfolio Management boosted its stake in Sangamo Therapeutics by 8.6% in the 3rd quarter. Meritage Portfolio Management now owns 85,000 shares of the biopharmaceutical company’s stock worth $74,000 after purchasing an additional 6,740 shares during the period. Point72 Asia Singapore Pte. Ltd. purchased a new position in Sangamo Therapeutics during the 2nd quarter valued at about $89,000. Finally, XTX Topco Ltd increased its position in shares of Sangamo Therapeutics by 167.8% during the third quarter. XTX Topco Ltd now owns 103,716 shares of the biopharmaceutical company’s stock valued at $90,000 after buying an additional 64,981 shares during the period. 56.93% of the stock is currently owned by hedge funds and other institutional investors.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.